Navigation Links
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Date:3/2/2013

PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab.  Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters.  The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications.  Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses).  The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo).  A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05).  The most common adverse events (AEs) were nasophar
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
2. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
5. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
8. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
9. Sanofi Pasteur to add 2D barcode to six more vaccines
10. Sanofi US Launches Collaborate Activate Innovation Challenge
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... July 7 Reportlinker.com announces that a new market ... , , ... Emerging Markets (Brazil, Russia, India) - Growing need for second- and ... , , ...
... have used a genetically reprogrammed herpes virus and an anti-vascular drug to ... still an elusive goal when treating humans with cancer, according to a ... , , , ... percent of patients with metastatic cancer survive beyond five years, despite the ...
Cached Medicine Technology:Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 2Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 3Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 4Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 5Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 6Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 7Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 8Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 9Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 10Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 11Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity 12Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 2Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 3Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 4
(Date:12/20/2014)... OH (PRWEB) December 20, 2014 ... contend they suffered uncontrollable bleeding and other serious ... Court, Eastern District of Louisiana for coordinated pretrial proceedings, ... on Multidistrict Litigation (JPML) issued an order Friday to ... actions pending in 22 federal courts to the Louisiana ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays ... the wayside until Christmas and the New Year are over. ... that burning desire to just escape it all and get ... Telluride with a no-fuss, affordable package. Montrose Days Inn will ... and ensure that all accommodations are met. Plus, everyone has ...
(Date:12/19/2014)... Silver Dollar City is picking up ... the first time ever, Silver Dollar City has a title ... 2015, listing the park’s wood coaster Outlaw Run as the ... announced this week, Silver Dollar City is named in CNN ... USA Today’s 10Best awards for “Best Public Lights Display,” and ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, ... respected cosmetic brand Juvéderm. Voluma XC treats volume loss ... Medspa at Hendrick is pleased to be able to ... to its clients. , Voluma is the first and ... treat the mid-face and cheek area. This non-invasive treatment ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
Breaking Medicine News(10 mins):Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... 28, 2008) Scientists at NanoBio Corporation have demonstrated ... topical treatment for cold sores (herpes labialis), NB-001, speeds ... systemic drugs but without safety or toxicity concerns. , ... that a topical agent can attain equivalent efficacy rates ...
... WASHINGTON, Oct. 28 In recognition of,Veterans Day, ... with the Prostate Cancer Education Council, and the,American ... and,education event in the Redskins players, locker room ... to be proactive about their,health., The event ...
... Did you know that one in six men ... prostate cancer occurs,every 2.5 minutes and a man dies ... men,s health first., Listen to this report from ... access video, audio, text, graphics and,photos for free and ...
... propofol tied to cardiac arrest in patients with a ... Use of the sedative propofol is associated with a high ... seizures, according to a study by researchers at the Mayo ... with refractory status epilepticus (RSE) -- prolonged seizures that don,t ...
... common, potentially lethal disease, survey shows , , TUESDAY, Oct. 28 ... for developing diabetes, too few perceive the threat it can ... In fact, most respondents feared shark bites, plane crashes or ... diabetes, according to the pollsters. , "We undertook the survey ...
... PHILADELPHIA, Oct. 28 The Family Planning,Council was recently ... Human Services for a total of $3 million. These ... areas: the,use of Natural Family Planning as a method ... women; and, creating a model program to,provide family planning ...
Cached Medicine News:Health News:Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift 2Health News:Washington Redskins Open FedExField Locker Room to ALL Military Veterans for Free Health Screenings 2Health News:Sedative Could Be Deadly in People With Seizures 2Health News:Too Few Understand Diabetes' Dangers 2Health News:Too Few Understand Diabetes' Dangers 3Health News:Local Organization Receives Multi-Million Dollar Grants for Natural Family Planning, HIV Testing and Family Planning Services for Men 2
Malis CMC-III Generator provides both coagulation and cutting outputs....
...
...
...
Medicine Products: